Eukaryotic ribosome

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

Retrieved on: 
Thursday, December 1, 2022
Transfer, Proxy, Regulation of tobacco by the U.S. Food and Drug Administration, AST, RMAS, Bangladesh Securities and Exchange Commission, Science, Degenerative disease, Food, RNA, Polycystic kidney disease, Autosome, Patient, Kidney, Royal commission, CF, Fast Track, European Commission, Eukaryotic ribosome, CUSIP, Orphan, Security (finance), Letter, Cancer, Cystic fibrosis, Mutation, FDA, Holding company, Auction

The new CUSIP number for the Companys common stock following the reverse stock split will be 29014R202.

Key Points: 
  • The new CUSIP number for the Companys common stock following the reverse stock split will be 29014R202.
  • As a result of the reverse stock split, every 40 shares of the Companys common stock issued and outstanding will be automatically reclassified into one new share of the Companys common stock.
  • The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.
  • Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted to give effect to the reverse stock split) on The Nasdaq Capital Market today, the last trading day immediately preceding the effective time of the reverse stock split.

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, RNA, Plasma, RMAS, Science, CF, Mutation, SEC, Clinical trial, Cancer, GLOBE, Patient, Royal commission, Research, Eukaryotic ribosome, COVID-19, Allele, Disease, COL4A3, File, European Commission, Degenerative disease, Cystic fibrosis, Proteinuria, Kidney disease, Safety, Genetic disorder, Patent, Judgement, COL4A5, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Private Securities Litigation Reform Act, Polycystic kidney disease, Hearing loss, FDA, Kidney, Food, Fast Track, Alport syndrome, Autosome, Forward-looking statement, Gene, COL4A4, Orphan, Pharmaceutical industry, Alport

Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Key Points: 
  • Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • Alport patients with nonsense mutations have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • This proof-of-concept clinical trial will include up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Retrieved on: 
Wednesday, September 14, 2022
SCC, CF, Safety, Orphan, COVID-19, Mutation, Kidney, FDA, Spirometry, Food, European Commission, Population, Kidney disease, Cell membrane, Degenerative disease, Judgement, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Allele, Clinical trial, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, File, FEV1, CFTR, Alport syndrome, Valencia CF Foundation, Polycystic kidney disease, Science, Fast Track, RMAS, NASDAQ, Autosome, Lung, RNA, Research, Conference, GLOBE, Royal commission, SEC, Cystic fibrosis, Patent, Eukaryotic ribosome, Disease, Silviculture, Pharmaceutical industry, Dietary supplement, Alport

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.
  • The Phase 2 combination clinical trial of ELX-02 was designed to evaluate safety and assess biological activity in G542X nonsense mutation Class 1 CF patients as monotherapy and in combination with ivacaftor.
  • Topline results are summarized below:
    ELX-02 was generally well tolerated in the trial, with no treatment-related serious adverse events noted.
  • ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473).

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Department, Financial compensation, FDA, CF, Mutation, Science, University of Chicago, Patient, Savannah State University Office of Graduate Studies and Sponsored Research, Kidney, CEO, Massachusetts Institute of Technology, United States Attorney General, GLOBE, Â, European Commission, CFA, Degenerative disease, Cancer, Initial public offering, RMAS, Eukaryotic ribosome, MBA, Department of Human Services and Health, Fast Track, Orphan, Humanitarian use licenses, Food, Autosome, BS, Royal commission, Roivant Sciences, RNA, Psoriasis, Polycystic kidney disease, University, Cystic fibrosis, Acquisition, JD, Regulation of tobacco by the U.S. Food and Drug Administration, Overactive bladder, NASDAQ, Uterine fibroid, Management, Pharmaceutical industry

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Wednesday, March 30, 2022
Disease, Autosome, Private Securities Litigation Reform Act, COL4A4, Plasma, Population, NASDAQ, Degenerative disease, COL4A3, Patent, Polycystic kidney disease, Eukaryotic ribosome, Forward-looking statement, Clinical trial, Kidney, Hearing loss, Mutation, Judgement, Proteinuria, SEC, Research, Program, Alport syndrome, Patient, Cancer, Kidney disease, Allele, RNA, Cystic fibrosis, Safety, RNA transfection, COVID-19, GLOBE, Gene, Genetic disorder, Science, RMAS, File, Pharmaceutical industry, COL4A5, Alport

WATERTOWN, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced it has expanded the ELX-02 development program to include the treatment of Alport syndrome, a rare kidney disease. Clinical testing of ELX-02 in Alport syndrome is expected to initiate in the second half of 2022, with topline results expected in the first half of 2023.

Key Points: 
  • Clinical testing of ELX-02 in Alport syndrome is expected to initiate in the second half of 2022, with topline results expected in the first half of 2023.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.
  • These patients have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • Eloxx intends to initiate a proof-of-concept clinical trial in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Retrieved on: 
Tuesday, March 29, 2022
Disease, Autosome, Company, CFTR, Private Securities Litigation Reform Act, Fast Track, Orphan, NASDAQ, Degenerative disease, Valencia CF Foundation, Patent, Polycystic kidney disease, Forward-looking statement, Eukaryotic ribosome, Clinical trial, European Medicines Agency, Kidney, Mutation, Judgement, Research, SEC, Cancer, Achievement, RNA, Food, Allele, Cystic fibrosis, Organoid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RNA transfection, COVID-19, GLOBE, Science, FDA, RMAS, Patient, CF, File, Pharmaceutical industry, Ivacaftor

WATERTOWN, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program. This is in addition to the previously announced partial funding of the global clinical trial program.

Key Points: 
  • Furthermore, this additional award from the CF Foundation extends our cash runway into the second quarter of 2023.
  • The CF Foundation has awarded funding of up to $15.9 million to support the ongoing ELX-02 global Phase 2 clinical program.
  • Eloxx will pay the CF Foundation royalties tiered to the actual level of funding from the CF Foundation.
  • ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473).

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

Retrieved on: 
Wednesday, November 17, 2021
Autosome, Safety, Spirometry, Cancer, Science, Private Securities Litigation Reform Act, Plasma, Division, Clinical trial, ET, Eukaryotic ribosome, NASDAQ, Lumacaftor/ivacaftor, RMAS, RNA, Doctor of Philosophy, Disease, Food, Cell membrane, European Medicines Agency, Degenerative disease, FEV1, COVID-19, Organoid, Research, Forward-looking statement, File, Judgement, Conference, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mutation, Kidney, CFTR, SEC, Polycystic kidney disease, Investigational New Drug, Cystic fibrosis, CF, Lung, Patent, Concentration ratio, Fast Track, Patient, FDA, Allele, Orphan, Pharmaceutical industry, Medical imaging

WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced positive topline results from the monotherapy arms of its Phase 2 clinical trial of ELX-02 in Class 1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation. ELX-02 was well tolerated and achieved a statistically significant 5.4mmol/L reduction in sweat chloride in patients at the1.5mg/kg/day dose.

Key Points: 
  • Based on the statistically significant monotherapy results observed at the 1.5mg/kg/day dose, planning for the advancement of ELX-02 into Phase 3 clinical development has started.
  • The Phase 2 clinical trial of ELX-02 was designed to evaluate safety and assess biological activity in G542X nonsense mutation Class 1 CF patients as monotherapy and in combination with ivacaftor.
  • Topline results for the intra-patient dose escalation monotherapy arms are summarized below:
    ELX-02 was generally well tolerated in the trial, with no treatment-related serious adverse events noted.
  • ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473).

Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Retrieved on: 
Thursday, October 7, 2021
Private Securities Litigation Reform Act, Company, RMAS, Forward-looking statement, Patent, COVID-19, CF, GLOBE, Cancer, Cystic fibrosis, Webcast, File, Eukaryotic ribosome, SEC, Kidney, Polycystic kidney disease, Autosome, Judgement, Science, Clinical trial, Mutation, Research, Nasdaq, Pharmaceutical industry

WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021. The event will include an update on the company’s cystic fibrosis programs and will feature Dr. Eitan Kerem, a globally renowned CF expert. The event is intended to provide insight into Eloxx’ CF programs, as data from the ongoing Phase 2 trials in CF are expected in the fourth quarter of 2021.Date: Tuesday, October 12, 2021Time: 10:00 a.m. ETDomestic Dial-in Number: (866) 913-8546International Dial-in Number: (210) 874-7715Conference ID: 8378144Live Webcast and Presentation Materials: accessible from the Company's website at www.eloxxpharma.com under Events and Presentations.

Key Points: 
  • WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021.
  • The event will include an update on the companys cystic fibrosis programs and will feature Dr. Eitan Kerem, a globally renowned CF expert.
  • The event is intended to provide insight into Eloxx CF programs, as data from the ongoing Phase 2 trials in CF are expected in the fourth quarter of 2021.
  • Live Webcast and Presentation Materials: accessible from the Company's website at www.eloxxpharma.com under Events and Presentations.

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

Retrieved on: 
Tuesday, October 5, 2021
Patent, Eukaryotic ribosome, Clinical trial, Partnership, Achievement, Private Securities Litigation Reform Act, Cancer, Patient, Kidney, Hercules, CEO, Autosome, RMAS, Science, COVID-19, Technology, Judgement, Mutation, Research, Polycystic kidney disease, Learning, Forward-looking statement, Cystic fibrosis, Nasdaq, NYSE, File, SEC, GLOBE, Security (finance), Pharmaceutical industry

WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies.

Key Points: 
  • WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies.
  • Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under the Companys existing debt facility.
  • The remaining funds under the new facility will be available in additional tranches upon the achievement of specific clinical milestones or other terms and conditions.
  • Hercules is pleased to enter into this financing partnership with Eloxx as it continues to advance its pipeline of both clinical and preclinical assets, said Janice Bourque, Managing Director at Hercules Capital.

Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations

Retrieved on: 
Thursday, September 9, 2021

WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations.

Key Points: 
  • WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations.
  • We are delighted to receive Fast Track Designation from the FDA for ELX-02 as the need for patients remains significant.
  • Fast Track Designation is granted to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medical need.
  • ELX-02 has previously been granted orphan drug designation by the FDA and orphan medicinal product designation by the European Medicines Agency.